Display options
Cite
Sorg H, Hoffmann JO, Hoffmann JN, et al. Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation. Intensive Care Med Exp. 2015;3(1):58doi: 10.1186/s40635-015-0058-x.
Sorg, H., Hoffmann, J. O., Hoffmann, J. N., & Vollmar, B. (2015). Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation. Intensive care medicine experimental, 3(1), 58. https://doi.org/10.1186/s40635-015-0058-x
Sorg, Heiko, et al. "Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation." Intensive care medicine experimental vol. 3,1 (2015): 58. doi: https://doi.org/10.1186/s40635-015-0058-x
Sorg H, Hoffmann JO, Hoffmann JN, Vollmar B. Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation. Intensive Care Med Exp. 2015 Dec;3(1):58. doi: 10.1186/s40635-015-0058-x. Epub 2015 Jul 09. PMID: 26215822; PMCID: PMC4495092.
Copy Download .nbib Format: NLM
Share it on

Intensive Care Med Exp. 2015 Dec;3(1):58. doi: 10.1186/s40635-015-0058-x. Epub 2015 Jul 09.

Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation.

Intensive care medicine experimental

Heiko Sorg, Julius O Hoffmann, Johannes N Hoffmann, Brigitte Vollmar

Affiliations

  1. Institute for Experimental Surgery, University Medicine Rostock, Schillingallee 69a, 18057, Rostock, Germany, [email protected].

PMID: 26215822 PMCID: PMC4495092 DOI: 10.1186/s40635-015-0058-x

Abstract

PURPOSE: Microvascular thrombosis during septic conditions is of essential clinical relevance, but the pathomechanisms are not yet completely understood. The purpose of this study was to study the distinguished differentiation of the interactions of inflammation and coagulation using antithrombin (AT), a mediator of anticoagulation and anti-inflammation.

METHODS: Using a thrombosis model in a cremaster muscle preparation of male C57Bl/6J mice (n = 83), we quantitatively assessed microvascular thrombus formation by using intravital fluorescence microscopy. Experimental groups consisted of animals treated with AT or with tryptophan(49)-blocked AT (TrypAT), which exerts only anticoagulant but no anti-inflammatory effects. To further see whether endothelial glycosaminoglycan (GAG) binding with consecutive prostacyclin (PGI2) release is mandatory for the anticoagulant process of AT, animals were administered heparin or indomethacin either alone or in combination with AT.

RESULTS: The antithrombotic capacity of AT significantly differs in the experimental groups in which anti-inflammation was antagonized. This is given by the significantly prolonged occlusion times (p < 0.05) and higher patency rates in case of application of AT alone; while all other groups in which the anti-inflammatory action of AT was blocked by TrypAT, heparin or indomethacin revealed thrombus kinetics comparable to controls.

CONCLUSIONS: The anti-inflammatory influence of AT is essentially linked to its anticoagulant effect in the microvascular system. Those specifications of the active profile of AT characterize the intimate interactions of the anticoagulant and anti-inflammatory pathways. This might be of relevance for AT as a therapeutic agent in critically diseased patients and the clinical understanding of microvascular thrombosis.

References

  1. Intensive Care Med. 1998 Apr;24(4):336-42 - PubMed
  2. J Thromb Haemost. 2011 Apr;9(4):779-89 - PubMed
  3. Thromb Haemost. 1997 Mar;77(3):408-23 - PubMed
  4. Blood Coagul Fibrinolysis. 1998 Nov;9 Suppl 3:S7-10 - PubMed
  5. Biochemistry. 1984 Apr 10;23(8):1730-7 - PubMed
  6. Langenbecks Arch Surg. 2007 May;392(3):285-95 - PubMed
  7. Thromb Res. 1984 Aug 1;35(3):319-34 - PubMed
  8. Am J Physiol. 1996 Jun;270(6 Pt 1):L921-30 - PubMed
  9. Crit Care Med. 2005 Feb;33(2):355-60 - PubMed
  10. JAMA. 2001 Oct 17;286(15):1869-78 - PubMed
  11. J Clin Invest. 2000 Aug;106(3):385-92 - PubMed
  12. J Thromb Haemost. 2006 Jan;4(1):90-7 - PubMed
  13. Blood. 2003 Apr 15;101(8):3029-36 - PubMed
  14. Microcirculation. 2008 May;15(4):269-82 - PubMed
  15. BMJ. 2006 Jun 3;332(7553):1302-8 - PubMed
  16. Shock. 1998 Aug;10(2):90-6 - PubMed
  17. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2415-9 - PubMed
  18. Am J Physiol Cell Physiol. 2000 Jul;279(1):C98-C107 - PubMed
  19. Blood Coagul Fibrinolysis. 2002 Dec;13(8):657-70 - PubMed
  20. Circulation. 1998 Jan 27;97(3):251-6 - PubMed
  21. J Lab Clin Med. 1999 Jun;133(6):557-65 - PubMed
  22. Brain Res. 1983 Oct 31;277(2):393-6 - PubMed
  23. Semin Hematol. 1991 Jan;28(1):3-9 - PubMed
  24. Ann Intensive Care. 2011 Jul 19;1(1):27 - PubMed
  25. Microcirculation. 2005 Apr-May;12(3):259-74 - PubMed
  26. Thromb Res. 1994 Jan 1;73(1):31-8 - PubMed
  27. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2680-7 - PubMed
  28. Crit Care Med. 2004 Sep;32(9):1851-9 - PubMed
  29. Crit Care. 2014 Jan 13;18(1):R13 - PubMed
  30. Pol Arch Med Wewn. 2014;124(6):321-8 - PubMed
  31. Thromb Haemost. 2002 Aug;88(2):242-52 - PubMed
  32. Thromb Haemost. 1995 May;73(5):868-72 - PubMed
  33. Blood. 2003 Nov 15;102(10):3609-14 - PubMed
  34. Thromb Haemost. 2006 May;95(5):850-6 - PubMed
  35. Shock. 1997 Nov;8(5):328-34 - PubMed
  36. Crit Care Med. 2013 Mar;41(3):867-73 - PubMed
  37. Biochem Biophys Res Commun. 1989 Sep 29;163(3):1404-11 - PubMed
  38. Blood Coagul Fibrinolysis. 1994 Feb;5(1):83-95 - PubMed
  39. Thromb Res. 2005;115(4):301-7 - PubMed
  40. Thromb Res. 2007;121(2):241-8 - PubMed
  41. PLoS One. 2011;6(5):e20062 - PubMed
  42. Virulence. 2014 Jan 1;5(1):73-9 - PubMed
  43. Thromb Res. 1995 Jul 15;79(2):175-86 - PubMed
  44. Crit Care Med. 2002 Jan;30(1):218-25 - PubMed
  45. Thromb Haemost. 2006 Sep;96(3):371-7 - PubMed
  46. Neth J Med. 2012 Apr;70(3):114-20 - PubMed
  47. Thromb Haemost. 2004 Jan;91(1):162-70 - PubMed
  48. Arch Biochem Biophys. 1984 Sep;233(2):712-20 - PubMed
  49. Crit Care. 2013 Dec 16;17(6):R297 - PubMed
  50. Thromb Haemost. 2014 Oct;112(4):640-8 - PubMed
  51. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77 - PubMed
  52. Crit Care Med. 2006 Feb;34(2):285-92 - PubMed
  53. Intensive Care Med. 2004 Jun;30(6):1032-40 - PubMed
  54. Ann Lab Med. 2014 Mar;34(2):85-91 - PubMed
  55. Thromb Haemost. 1994 Oct;72 (4):617-21 - PubMed
  56. Chest. 1993 Sep;104(3):882-8 - PubMed
  57. Blood. 2004 Nov 15;104(10):3173-80 - PubMed
  58. Semin Thromb Hemost. 1997;23(6):583-90 - PubMed
  59. J Biol Chem. 1984 Jan 25;259(2):939-41 - PubMed
  60. Crit Care Med. 2013 Feb;41(2):580-637 - PubMed
  61. Diabetologia. 2006 Apr;49(4):792-800 - PubMed
  62. Transpl Int. 2006 Jun;19(6):458-65 - PubMed
  63. Intensive Care Med. 1998 Jul;24(7):663-72 - PubMed
  64. Thromb Res. 1998 Mar 1;89(5):233-41 - PubMed
  65. Crit Care Med. 2000 Aug;28(8):2881-6 - PubMed

Publication Types